89–006 

111TH CONGRESS REPORT " ! HOUSE OF REPRESENTATIVES 2d Session 111–633 

GESTATIONAL DIABETES ACT OF 2010 

SEPTEMBER 28, 2010.—Committed to the Committee of the Whole House on the 

State of the Union and ordered to be printed 

Mr. WAXMAN, from the Committee on Energy and Commerce, 

submitted the following 

R E P O R T 

[To accompany H.R. 5354] 

[Including cost estimate of the Congressional Budget Office] 

The Committee on Energy and Commerce, to whom was referred 

the bill (H.R. 5354) to establish an Advisory Committee on Gestational Diabetes, to provide grants to better understand and reduce 

gestational diabetes, and for other purposes, having considered the 

same, report favorably thereon with amendments and recommend 

that the bill as amended do pass. 

CONTENTS 

Page 

Amendment .............................................................................................................. 2 

Purpose and Summary ............................................................................................ 4 

Background and Need for Legislation .................................................................... 4 

Committee Consideration ........................................................................................ 4 

Committee Votes ...................................................................................................... 4 

Committee Oversight Findings and Recommendations ........................................ 5 

New Budget Authority, Entitlement Authority, and Tax Expenditures ............. 5 

Statement of General Performance Goals and Objectives .................................... 5 

Constitutional Authority Statement ...................................................................... 5 

Earmarks and Tax and Tariff Benefits .................................................................. 5 

Federal Advisory Committee Statement ................................................................ 5 

Applicability of Law to the Legislative Branch ..................................................... 5 

Federal Mandates Statement ................................................................................. 5 

Committee Cost Estimate ....................................................................................... 6 

Congressional Budget Office Cost Estimate .......................................................... 6 

Section-by-Section Analysis of the Legislation ...................................................... 7 

Explanation of Amendment .................................................................................... 8 

Changes in Existing Law Made by the Bill, as Reported ..................................... 8 


smartinez on DSKB9S0YB1PROD with REPORTS
2 

AMENDMENT

The amendments are as follows: 

Strike all after the enacting clause and insert the following: 

SECTION 1. SHORT TITLE. 

This Act may be cited as the ‘‘Gestational Diabetes Act of 2010’’ or the ‘‘GEDI Act’’. 

SEC. 2. GESTATIONAL DIABETES. 

Part B of title III of the Public Health Service Act (42 U.S.C. 243 et seq.) is amended by adding after section 317H the following: 

‘‘SEC. 317H–1. GESTATIONAL DIABETES. 

‘‘(a) UNDERSTANDING AND MONITORING GESTATIONAL DIABETES.— 

‘‘(1) IN GENERAL.—The Secretary, acting through the Director of the Centers for 

Disease Control and Prevention, in consultation with the Diabetes Mellitus 

Interagency Coordinating Committee established under section 429 and representatives of appropriate national health organizations, shall develop a 

multisite gestational diabetes research project within the diabetes program of 

the Centers for Disease Control and Prevention to expand and enhance surveillance data and public health research on gestational diabetes. 

‘‘(2) AREAS TO BE ADDRESSED.—The research project developed under paragraph 

(1) shall address— 

‘‘(A) procedures to establish accurate and efficient systems for the collection 

of gestational diabetes data within each State and commonwealth, territory, 

or possession of the United States; 

‘‘(B) the progress of collaborative activities with the National Vital Statistics System, the National Center for Health Statistics, and State health departments with respect to the standard birth certificate, in order to improve 

surveillance of gestational diabetes; 

‘‘(C) postpartum methods of tracking women with gestational diabetes after 

delivery as well as targeted interventions proven to lower the incidence of 

type 2 diabetes in that population; 

‘‘(D) variations in the distribution of diagnosed and undiagnosed gestational 

diabetes, and of impaired fasting glucose tolerance and impaired fasting 

glucose, within and among groups of women; and 

‘‘(E) factors and culturally sensitive interventions that influence risks and 

reduce the incidence of gestational diabetes and related complications during childbirth, including cultural, behavioral, racial, ethnic, geographic, demographic, socioeconomic, and genetic factors. 

‘‘(3) REPORT.—Not later than 2 years after the date of the enactment of this section, and annually thereafter, the Secretary shall generate a report on the findings and recommendations of the research project including prevalence of gestational diabetes in the multisite area and disseminate the report to the appropriate Federal and non-Federal agencies. 

‘‘(b) EXPANSION OF GESTATIONAL DIABETES RESEARCH.— 

‘‘(1) IN GENERAL.—The Secretary shall expand and intensify public health research regarding gestational diabetes. Such research may include— 

‘‘(A) developing and testing novel approaches for improving postpartum diabetes testing or screening and for preventing type 2 diabetes in women with 

a history of gestational diabetes; and 

‘‘(B) conducting public health research to further understanding of the epidemiologic, socioenvironmental, behavioral, translation, and biomedical factors and health systems that influence the risk of gestational diabetes and 

the development of type 2 diabetes in women with a history of gestational 

diabetes. 

‘‘(2) AUTHORIZATION OF APPROPRIATIONS.—There is authorized to be appropriated to carry out this subsection $5,000,000 for each fiscal year 2012 through 

2016. 

‘‘(c) DEMONSTRATION GRANTS TO LOWER THE RATE OF GESTATIONAL DIABETES.— 

‘‘(1) IN GENERAL.—The Secretary, acting through the Director of the Centers for 

Disease Control and Prevention, shall award grants, on a competitive basis, to 

eligible entities for demonstration projects that implement evidence-based interventions to reduce the incidence of gestational diabetes, the recurrence of gestational diabetes in subsequent pregnancies, and the development of type 2 diabetes in women with a history of gestational diabetes. 

‘‘(2) PRIORITY.—In making grants under this subsection, the Secretary shall give 

priority to projects focusing on— 


smartinez on DSKB9S0YB1PROD with REPORTS
3 

‘‘(A) helping women who have 1 or more risk factors for developing gestational diabetes; 

‘‘(B) working with women with a history of gestational diabetes during a 

previous pregnancy; 

‘‘(C) providing postpartum care for women with gestational diabetes; 

‘‘(D) tracking cases where women with a history of gestational diabetes developed type 2 diabetes; 

‘‘(E) educating mothers with a history of gestational diabetes about the increased risk of their child developing diabetes; 

‘‘(F) working to prevent gestational diabetes and prevent or delay the development of type 2 diabetes in women with a history of gestational diabetes; 

and 

‘‘(G) achieving outcomes designed to assess the efficacy and cost-effectiveness of interventions that can inform decisions on long-term sustainability, 

including third-party reimbursement. 

‘‘(3) APPLICATION.—An eligible entity desiring to receive a grant under this subsection shall submit to the Secretary— 

‘‘(A) an application at such time, in such manner, and containing such information as the Secretary may require; and 

‘‘(B) a plan to— 

‘‘(i) lower the rate of gestational diabetes during pregnancy; or 

‘‘(ii) develop methods of tracking women with a history of gestational 

diabetes and develop effective interventions to lower the incidence of 

the recurrence of gestational diabetes in subsequent pregnancies and 

the development of type 2 diabetes. 

‘‘(4) USES OF FUNDS.—An eligible entity receiving a grant under this subsection 

shall use the grant funds to carry out demonstration projects described in paragraph (1), including— 

‘‘(A) expanding community-based health promotion education, activities, 

and incentives focused on the prevention of gestational diabetes and development of type 2 diabetes in women with a history of gestational diabetes; 

‘‘(B) aiding State- and tribal-based diabetes prevention and control programs to collect, analyze, disseminate, and report surveillance data on 

women with, and at risk for, gestational diabetes, the recurrence of gestational diabetes in subsequent pregnancies, and, for women with a history 

of gestational diabetes, the development of type 2 diabetes; and 

‘‘(C) training and encouraging health care providers— 

‘‘(i) to promote risk assessment, high-quality care, and self-management 

for gestational diabetes and the recurrence of gestational diabetes in 

subsequent pregnancies; and 

‘‘(ii) to prevent the development of type 2 diabetes in women with a history of gestational diabetes, and its complications in the practice settings of the health care providers. 

‘‘(5) REPORT.—Not later than 4 years after the date of the enactment of this section, the Secretary shall prepare and submit to the Congress a report concerning the results of the demonstration projects conducted through the grants 

awarded under this subsection. 

‘‘(6) DEFINITION OF ELIGIBLE ENTITY.—In this subsection, the term ‘eligible entity’ means a nonprofit organization (such as a nonprofit academic center or community health center) or a State, tribal, or local health agency. 

‘‘(7) AUTHORIZATION OF APPROPRIATIONS.—There is authorized to be appropriated to carry out this subsection $5,000,000 for each fiscal year 2012 through 

2016. 

‘‘(d) POSTPARTUM FOLLOW-UP REGARDING GESTATIONAL DIABETES.—The Secretary, 

acting through the Director of the Centers for Disease Control and Prevention, shall 

work with the State- and tribal-based diabetes prevention and control programs assisted by the Centers to encourage postpartum follow-up after gestational diabetes, 

as medically appropriate, for the purpose of reducing the incidence of gestational diabetes, the recurrence of gestational diabetes in subsequent pregnancies, the development of type 2 diabetes in women with a history of gestational diabetes, and related complications.’’. 

Amend the title so as to read: 

A bill to provide grants to better understand and reduce gestational diabetes, and 

for other purposes. 


smartinez on DSKB9S0YB1PROD with REPORTS
4 

PURPOSE AND SUMMARY

H.R. 5354, the ‘‘Gestational Diabetes Act of 2010’’ or the ‘‘GEDI 

Act,’’ was introduced on May 20, 2010, by Rep. Eliot L. Engel (D– 

NY) and referred to the Committee on Energy and Commerce. 

The goal of H.R. 5354 is to expand and intensify research on gestational diabetes and to provide grants to better understand and 

reduce the incidence of this disease. 

BACKGROUND AND NEED FOR LEGISLATION

Gestational Diabetes Mellitus (GDM)—generally known as gestational diabetes—is high blood sugar that starts or is first diagnosed 

during pregnancy. According to the Centers for Disease Control 

and Prevention (CDC) gestational diabetes affects between 3% and 

7% of all pregnancies in the United States. It can have negative 

health effects on both mothers and their babies—an estimated 40% 

to 60% of women with gestational diabetes will develop type 2 diabetes within 10 years; babies born to mothers with the disease are 

at risk for having a high birth weight. Gestational diabetes also 

disproportionately affects minority populations. 

Gestational diabetes represents less than 1% of the diabetes burden in the United States, yet its impact on maternal and child 

health is significant, and federal support for research on the disease has been limited. Increased research is needed to better understand the risk factors for the disease and to develop evidencebased intervention strategies. 

COMMITTEE CONSIDERATION

H.R. 5354, the ‘‘Gestational Diabetes Act of 2010’’ or the ‘‘GEDI 

Act,’’ was introduced by Mr. Engel of New York on May 20, 2010, 

and referred to the Committee on Energy and Commerce. The bill 

was subsequently referred to the Subcommittee on Health on May 

21, 2010. On September 15, 2010, the Subcommittee held a legislative hearing on the bill. The Subcommittee met in open markup 

session to consider H.R. 5354 on September 16, 2010. An amendment in the nature of a substitute (manager’s amendment) by Mr. 

Engel was adopted by a voice vote. Subsequently, H.R. 5354 was 

favorably forwarded to the full Committee, amended, by a voice 

vote. 

On September 23, 2010, the Committee on Energy and Commerce met in open markup session to consider H.R. 5354, as approved by the Subcommittee on Health. There were no amendments offered in full Committee and subsequently the Committee 

ordered H.R. 5354 favorably reported to the House, as amended by 

the Subcommittee on Health, by a voice vote. 

COMMITTEE VOTES

Clause 3(b) of rule XIII of the Rules of the House of Representatives requires the Committee to list each record vote on the motion 

to report legislation and amendments thereto. A motion by Mr. 

Waxman ordering H.R. 5354 reported to the House, as amended, 

was approved by a voice vote. There were no record votes taken 

during consideration of this bill. 


smartinez on DSKB9S0YB1PROD with REPORTS
5 

COMMITTEE OVERSIGHT FINDINGS AND RECOMMENDATIONS

In compliance with clause 3(c)(1) of rule XIII and clause (2)(b)(1) 

of rule X of the Rules of the House of Representatives, the oversight findings and recommendations of the Committee are reflected 

in the descriptive portions of this report, including the finding that 

increased research is needed to better understand the risk factors 

for gestational diabetes and to develop evidence-based intervention 

strategies. 

NEW BUDGET AUTHORITY, ENTITLEMENT AUTHORITY, AND TAX

EXPENDITURES

Regarding compliance with clause 3(c)(2) of rule XIII of the Rules 

of the House of Representatives, the Committee finds that H.R. 

5354 would result in no new budget authority, entitlement authority, or tax expenditures or revenues. 

STATEMENT OF GENERAL PERFORMANCE GOALS AND OBJECTIVES

In accordance with clause 3(c)(4) of rule XIII of the Rules of the 

House of Representatives, the performance goals and objectives of 

the Committee are reflected in the descriptive portions of this report, including the goal to support increased research on gestational diabetes. 

CONSTITUTIONAL AUTHORITY STATEMENT

Pursuant to clause 3(d)(1) of rule XIII of the Rules of the House 

of Representatives, the Committee finds that the constitutional authority for H.R. 5354 is provided under article I, section 8, clauses 

3 and 18 of the Constitution of the United States. 

EARMARKS AND TAX AND TARIFF BENEFITS

H.R. 5354 does not contain any congressional earmarks, limited 

tax benefits, or limited tariff benefits as defined in clause 9 of rule 

XXI of the Rules of the House of Representatives. 

FEDERAL ADVISORY COMMITTEE STATEMENT

The Committee finds that the legislation does not establish or 

authorize the establishment of an advisory committee within the 

definition of 5 U.S.C. App., section 5(b) of the Federal Advisory 

Committee Act. 

APPLICABILITY OF LAW TO THE LEGISLATIVE BRANCH

Section 102(b)(3) of Public Law 104–1 requires a description of 

the application of this bill to the legislative branch where the bill 

relates to terms and conditions of employment or access to public 

services and accommodations. H.R. 5354 contains no such provisions. 

FEDERAL MANDATES STATEMENT

Section 423 of the Congressional Budget and Impoundment Control Act of 1974 (as amended by section 101(a)(2) of the Unfunded 

Mandates Reform Act, Public Law 104–4) requires a statement on 

whether the provisions of the report include unfunded mandates. 


smartinez on DSKB9S0YB1PROD with REPORTS
6 

In compliance with this requirement the Committee adopts as its 

own the analysis of federal mandates prepared by the Director of 

the Congressional Budget Office regarding H.R. 5354. 

COMMITTEE COST ESTIMATE

Pursuant to clause 3(d)(2) of rule XIII of the Rules of the House 

of Representatives, the Committee adopts as its own the cost estimate of H.R. 5354 prepared by the Director of the Congressional 

Budget Office pursuant to section 402 of the Congressional Budget 

Act of 1974. 

CONGRESSIONAL BUDGET OFFICE COST ESTIMATE

With respect to the requirements of clause (3)(c)(3) of rule XIII 

of the Rules of the House of Representatives and section 402 of the 

Congressional Budget Act of 1974, the Committee has received the 

following cost estimate for H.R. 5354 from the Director of Congressional Budget Office: 

SEPTEMBER 24, 2010. 

Hon. HENRY A. WAXMAN, 

Chairman, Committee on Energy and Commerce, 

House of Representatives, Washington, DC. 

DEAR MR. CHAIRMAN: The Congressional Budget Office has prepared the enclosed cost estimate for H.R. 5354, the Gestational Diabetes Act of 2010. 

If you wish further details on this estimate, we will be pleased 

to provide them. The CBO staff contact is Mindy Cohen. 

Sincerely, 

DOUGLAS W. ELMENDORF. 

Enclosure. 

H.R. 5354—Gestational Diabetes Act of 2010 

Summary: H.R. 5354 would require the Secretary of the Department of Health and Human Services (HHS) to develop research 

projects and award grants for the purposes of tracking and reducing the prevalence of gestational diabetes. Assuming appropriation 

of the specified amounts, CBO estimates that implementing H.R. 

5354 would cost $32 million over the 2011–2015 period. Enacting 

H.R. 5354 would not affect direct spending or revenues; therefore, 

pay-as-you-go procedures do not apply. 

H.R. 5354 contains no intergovernmental or private-sector mandates as defined in the Unfunded Mandates Reform Act (UMRA). 

Estimated cost to the Federal Government: The estimated budgetary impact of H.R. 5354 is shown in the following table. The costs 

of this legislation fall within budget function 550 (health). 

By fiscal year, in millions of dollars— 

2011 2012 2013 2014 2015 2011– 

2015 

CHANGES IN SPENDING SUBJECT TO APPROPRIATION 

Authorization Level ........................................................... 0 10 10 10 10 40 

Estimated Outlays ............................................................ 0 4 8 10 10 32 


smartinez on DSKB9S0YB1PROD with REPORTS
7 

Basis of estimate: H.R. 5354 would require the Secretary of HHS, 

acting through the Director of the Center for Disease Control and 

Prevention (CDC), to conduct research and grant activities relating 

to gestational diabetes. For example, the bill would require CDC to 

expand surveillance data and public health research, to test approaches for screening for the disease, and to award grants to entities that implement interventions to reduce the incidence of the 

disease. 

H.R. 5354 would authorize appropriations for fiscal years 2012 

through 2016 of $5 million a year for the research activities and 

$5 million a year for the grant activities. Based on historical spending patterns for similar activities, and assuming appropriation of 

the specified amounts, CBO estimates that implementing H.R. 

5354 would cost $32 million over the 2012–2015 period, and an additional $18 million after 2015. 

Pay-As-You-Go considerations: None. 

Intergovernmental and private-sector impact: H.R. 5354 contains 

no intergovernmental or private-sector mandates as defined in 

UMRA. Grant funds authorized in the bill would benefit states that 

implement programs to reduce the incidence of gestational diabetes. 

Estimate prepared by: Federal costs: Mindy Cohen; Impact on 

state, local, and tribal governments: Lisa Ramirez-Branum; Impact 

on the private sector: Sarah Axeen. 

Estimate approved by: Holly Harvey, Deputy Assistant Director 

for Budget Analysis. 

SECTION-BY-SECTION ANALYSIS OF THE LEGISLATION

Section 1. Short title 

Section 1 designates that the short title may be cited as the 

‘‘Gestational Diabetes Act of 2010’’ or the ‘‘GEDI Act.’’ 

Section 2. Gestational Diabetes 

Section 2 establishes a new section 317H–1 in the Public Health 

Service Act (PHSA) on gestational diabetes. This section includes 

the following provisions: 

Subsection (a) requires the Secretary of Health and Human Services (HHS), acting through the Director of the Centers for Disease 

Control and Prevention (CDC), and in consultation with the HHS 

Diabetes Mellitus Interagency Coordinating Committee (DMICC) 

(established under section 429 of the Public Health Service Act), to 

develop a multisite, gestational diabetes research project at CDC to 

expand and enhance surveillance data and public health research 

on gestational diabetes. 

Subsection (b) requires the Secretary to expand and intensify 

public health research on gestational diabetes research. Such research may include (1) the development and testing of new approaches for improving postpartum diabetes screening and for preventing type 2 diabetes in women with a history of gestational diabetes; and (2) research to further understand various factors that 

influence the risk of gestational diabetes and the development of 

type 2 diabetes in women with a history of gestational diabetes. 

The Act authorizes $5 million to support these research activities 

in each of FY2012 through FY2016. 


smartinez on DSKB9S0YB1PROD with REPORTS
8 

Subsection (c) requires the Secretary, acting through the CDC 

Director, to award grants to non-profit organizations or state or 

local health agencies for demonstration projects to support various 

activities designed to implement evidence-based interventions to reduce the incidence of gestational diabetes and its recurrence and to 

prevent type 2 diabetes after pregnancy. The Act authorizes $5 million to fund these grants in each of FY2012 through FY2016. 

Subsection (d) requires the Secretary, acting through the CDC 

Director, to work with state and tribal-based diabetes prevention 

and control programs to encourage postpartum screenings after a 

diagnosis of gestational diabetes to reduce (1) the incidence of gestational diabetes and its recurrence; and (2) the progression to type 

2 diabetes and its related complications. 

EXPLANATION OF AMENDMENT

During the Subcommittee on Health markup, Mr. Engel of New 

York offered an amendment in the nature of a substitute (manager’s amendment), which was adopted by a voice vote. The substance of the substitute amendment is reflected in the section-bysection analysis contained in this report. 

CHANGES IN EXISTING LAW MADE BY THE BILL, AS REPORTED

In compliance with clause 3(e) of rule XIII of the Rules of the 

House of Representatives, changes in existing law made by the bill, 

as reported, are shown as follows (new matter is printed in italic 

and existing law in which no change is proposed is shown in 

roman): 

PUBLIC HEALTH SERVICE ACT 

* * * * * * * 

TITLE III—GENERAL POWERS AND DUTIES OF PUBLIC 

HEALTH SERVICE 

* * * * * * * 

PART B—FEDERAL-STATE COOPERATION

* * * * * * * 

SEC. 317H–1. GESTATIONAL DIABETES. 

(a) UNDERSTANDING AND MONITORING GESTATIONAL DIABETES.— 

(1) IN GENERAL.—The Secretary, acting through the Director 

of the Centers for Disease Control and Prevention, in consultation with the Diabetes Mellitus Interagency Coordinating Committee established under section 429 and representatives of appropriate national health organizations, shall develop a 

multisite gestational diabetes research project within the diabetes program of the Centers for Disease Control and Prevention 

to expand and enhance surveillance data and public health research on gestational diabetes. 

(2) AREAS TO BE ADDRESSED.—The research project developed 

under paragraph (1) shall address— 

(A) procedures to establish accurate and efficient systems 

for the collection of gestational diabetes data within each 


smartinez on DSKB9S0YB1PROD with REPORTS
9 

State and commonwealth, territory, or possession of the 

United States; 

(B) the progress of collaborative activities with the National Vital Statistics System, the National Center for 

Health Statistics, and State health departments with respect to the standard birth certificate, in order to improve 

surveillance of gestational diabetes; 

(C) postpartum methods of tracking women with gestational diabetes after delivery as well as targeted interventions proven to lower the incidence of type 2 diabetes in 

that population; 

(D) variations in the distribution of diagnosed and 

undiagnosed gestational diabetes, and of impaired fasting 

glucose tolerance and impaired fasting glucose, within and 

among groups of women; and 

(E) factors and culturally sensitive interventions that influence risks and reduce the incidence of gestational diabetes and related complications during childbirth, including 

cultural, behavioral, racial, ethnic, geographic, demographic, socioeconomic, and genetic factors. 

(3) REPORT.—Not later than 2 years after the date of the enactment of this section, and annually thereafter, the Secretary 

shall generate a report on the findings and recommendations of 

the research project including prevalence of gestational diabetes 

in the multisite area and disseminate the report to the appropriate Federal and non-Federal agencies. 

(b) EXPANSION OF GESTATIONAL DIABETES RESEARCH.— (1) IN GENERAL.—The Secretary shall expand and intensify 

public health research regarding gestational diabetes. Such research may include— 

(A) developing and testing novel approaches for improving postpartum diabetes testing or screening and for preventing type 2 diabetes in women with a history of gestational diabetes; and 

(B) conducting public health research to further understanding of the epidemiologic, socioenvironmental, behavioral, translation, and biomedical factors and health systems that influence the risk of gestational diabetes and the 

development of type 2 diabetes in women with a history of 

gestational diabetes. 

(2) AUTHORIZATION OF APPROPRIATIONS.—There is authorized 

to be appropriated to carry out this subsection $5,000,000 for 

each fiscal year 2012 through 2016. 

(c) DEMONSTRATION GRANTS TO LOWER THE RATE OF GESTATIONAL DIABETES.— 

(1) IN GENERAL.—The Secretary, acting through the Director 

of the Centers for Disease Control and Prevention, shall award 

grants, on a competitive basis, to eligible entities for demonstration projects that implement evidence-based interventions to reduce the incidence of gestational diabetes, the recurrence of gestational diabetes in subsequent pregnancies, and the development of type 2 diabetes in women with a history of gestational 

diabetes. 

(2) PRIORITY.—In making grants under this subsection, the 

Secretary shall give priority to projects focusing on— 


smartinez on DSKB9S0YB1PROD with REPORTS
10 

(A) helping women who have 1 or more risk factors for 

developing gestational diabetes; 

(B) working with women with a history of gestational diabetes during a previous pregnancy; 

(C) providing postpartum care for women with gestational diabetes; 

(D) tracking cases where women with a history of gestational diabetes developed type 2 diabetes; 

(E) educating mothers with a history of gestational diabetes about the increased risk of their child developing diabetes; 

(F) working to prevent gestational diabetes and prevent 

or delay the development of type 2 diabetes in women with 

a history of gestational diabetes; and 

(G) achieving outcomes designed to assess the efficacy 

and cost-effectiveness of interventions that can inform decisions on long-term sustainability, including third-party reimbursement. 

(3) APPLICATION.—An eligible entity desiring to receive a 

grant under this subsection shall submit to the Secretary— 

(A) an application at such time, in such manner, and 

containing such information as the Secretary may require; 

and 

(B) a plan to— 

(i) lower the rate of gestational diabetes during pregnancy; or 

(ii) develop methods of tracking women with a history of gestational diabetes and develop effective interventions to lower the incidence of the recurrence of gestational diabetes in subsequent pregnancies and the development of type 2 diabetes. 

(4) USES OF FUNDS.—An eligible entity receiving a grant 

under this subsection shall use the grant funds to carry out 

demonstration projects described in paragraph (1), including— 

(A) expanding community-based health promotion education, activities, and incentives focused on the prevention 

of gestational diabetes and development of type 2 diabetes 

in women with a history of gestational diabetes; 

(B) aiding State- and tribal-based diabetes prevention 

and control programs to collect, analyze, disseminate, and 

report surveillance data on women with, and at risk for, 

gestational diabetes, the recurrence of gestational diabetes 

in subsequent pregnancies, and, for women with a history 

of gestational diabetes, the development of type 2 diabetes; 

and 

(C) training and encouraging health care providers— 

(i) to promote risk assessment, high-quality care, and 

self-management for gestational diabetes and the recurrence of gestational diabetes in subsequent pregnancies; 

and 

(ii) to prevent the development of type 2 diabetes in 

women with a history of gestational diabetes, and its 

complications in the practice settings of the health care 

providers. 


smartinez on DSKB9S0YB1PROD with REPORTS
11 

(5) REPORT.—Not later than 4 years after the date of the enactment of this section, the Secretary shall prepare and submit 

to the Congress a report concerning the results of the demonstration projects conducted through the grants awarded 

under this subsection. 

(6) DEFINITION OF ELIGIBLE ENTITY.—In this subsection, the 

term ‘‘eligible entity’’ means a nonprofit organization (such as 

a nonprofit academic center or community health center) or a 

State, tribal, or local health agency. 

(7) AUTHORIZATION OF APPROPRIATIONS.—There is authorized 

to be appropriated to carry out this subsection $5,000,000 for 

each fiscal year 2012 through 2016. 

(d) POSTPARTUM FOLLOW-UP REGARDING GESTATIONAL DIABE- TES.—The Secretary, acting through the Director of the Centers for 

Disease Control and Prevention, shall work with the State- and 

tribal-based diabetes prevention and control programs assisted by 

the Centers to encourage postpartum follow-up after gestational diabetes, as medically appropriate, for the purpose of reducing the incidence of gestational diabetes, the recurrence of gestational diabetes 

in subsequent pregnancies, the development of type 2 diabetes in 

women with a history of gestational diabetes, and related complications. 

* * * * * * * 

Æ 


smartinez on DSKB9S0YB1PROD with REPORTS